Alvimedica introduces SFA sirolimus-eluting stent
Ngày 10/02/2020 09:43 | Lượt xem: 26

At the Leipzig Interventional Course 2020 (LINC; 28–31 January, Leipzig, Germany), Alvimedica held a Lunch Symopsium in which they introduced a new in-stent treatment of superficial femoral artery (SFA) lesions—Nitides—a technology based on the sustained release of Sirolimus by a SX polymer-free platform.

In one lecture, Stefan Müller-Hülsbeck (Diako Hospital, Flensburg, Germany) underlined the need for drug-eluting technologies (DET) in the SFA region, demonstrating the key contribution provided by the drug in optimising device efficacy and identifying the key DES role in specific anatomical and pathological SFA settings. In light of paclitaxel safety concerns, Müller-Hülsbeck concluded his talk saying that “the availability of an alternative DES—able to slowly elute a non-cytotoxic drug which results in equivalent efficacy—is warranted, as it is worth investing in innovative research in order to improve patient’s clinical outcome”.

Konstantinos Katsanos (University of Patras, Patras, Greece), indicating sirolimus as the non-cytotoxic drug which may substitute paclitaxel thanks to a more favourable biological profile and high anti-restenotic properties, concluded his talk by asking: “In light of paclitaxel safety concerns in the lower limbs may sirolimus be an alternative?”

After these two presentations, Andrea Kahlberg (San Raffaele Scientific Institute, Milan, Italy) took the stage introducing to the audience Nitides, the sirolimus-eluting SX DES which has the potential to be a game changer in current SFA DES landscape. This device is based on three unique technologies:

  • Abluminal Reservoir Technology, which allows a sustain release of the drug through a polymer free platform
  • Amphilimus™ formulation (Sirolimus + Fatty acid), which allows a homogeneous distribution of the drug only towards the vessel wall
  • Bio Inducer Surface, a pure Carbon coating which allows an increased haemo- and bio- compatibility of the nitinol platform

The clinical proof of Nitides rationale was shown by  Dierk Scheinert (University Hospital Leipzig, Leipzig, Germany) who presented the two-year results of the ILLUMINA first-in-human study which has enrolled 100 patients. In his talk he has highlighted that, although the study included complex patients and complex lesions (two patients Rutherford 5, lesions up to 140mm and 55% of moderate/heavy calcifications), the results at 24 months have been remarkable: 91.9% Freedom from device related MAE confirms long-term excellent SAFETY performance, while 93.1% Freedom from TLR states that the high product EFFICACY is maintained over long time.

After a discussion among all the speakers, Ralf Langhoff (Humboldt University Berlin,
Berlin, Germany) concluded this symposium saying “We now have a drug-based and stent based approach, even without a toxic PTX effect on the vessel wall: NiTiDES showed superb 24 month-data for a SFA DES strategy with the lowest TLR rate ever”.

Source VascularNews

Duc Tin Clinic

Print Chia sẽ qua facebook bài: Alvimedica introduces SFA sirolimus-eluting stent Chia sẽ qua google bài: Alvimedica introduces SFA sirolimus-eluting stent Chia sẽ qua twitter bài: Alvimedica introduces SFA sirolimus-eluting stent Chia sẽ qua MySpace bài: Alvimedica introduces SFA sirolimus-eluting stent Chia sẽ qua LinkedIn bài: Alvimedica introduces SFA sirolimus-eluting stent Chia sẽ qua stumbleupon bài: Alvimedica introduces SFA sirolimus-eluting stent Chia sẽ qua icio bài: Alvimedica introduces SFA sirolimus-eluting stent Chia sẽ qua digg bài: Alvimedica introduces SFA sirolimus-eluting stent Chia sẽ qua yahoo bài: Alvimedica introduces SFA sirolimus-eluting stent Chia sẽ qua yahoo bài: Alvimedica introduces SFA sirolimus-eluting stent Chia sẽ qua yahoo bài: Alvimedica introduces SFA sirolimus-eluting stent Chia sẽ qua yahoo bài: Alvimedica introduces SFA sirolimus-eluting stent

Tin tức liên quan

CUSTOMER REVIEWS

  • I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

    I sincerely thank you !. Tel: 0938303275

  • Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

    Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

  • As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

  • The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

  • I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.

Search
Customer support

    Phone: (028) 3981 2678
    Mobile: 0903 839 878 - 0909 384 389

TOP